In high-income countries, more than 80% of children diagnosed with cancer will survive. Yet in some low- and middle-income ...

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on United Therapeutics (UTHR – Research Report) and ...

Teva's stock is a speculative buy with potential upside if biosimilars succeed, but risks remain high due to debt and ...

In a report released yesterday, Jason Gerberry from Bank of America Securities reiterated a Buy rating on Arcellx Inc (ACLX – Research Report).

The company is leaning on its subcutaneous technology to deliver long-acting options that could prevent patients from cycling through drugs.

The MSSG solidarity mechanism enables medicine sharing between EU states, with companies now required to report on drug ...

DelveInsight's High Potency Active Pharmaceutical Ingredients Market Insights report provides the current and forecast market ...